GlassScriptPhysician profile
Mary M Clapp
NPI 1982041463
$1,564.08
in general payments reported to CMS, 2019-2025
17 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $268 · 2021: $220 · 2022: $205 · 2023: $493 · 2024: $241 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $609.19 | 2020-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $266.31 | 2020-2022 | |
| Lilly USA, LLC | $137.27 | 2020-2023 | Mounjaro |
| Astellas Pharma US INC | $117.96 | 2021-2023 | Veozah |
| Nestle Healthcare Nutrition INC. | $103.34 | 2023 | |
| Abbvie INC. | $83.54 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $39.99 | 2020-2021 | |
| Genentech USA, INC. | $36.15 | 2020 | |
| Amarin Pharma, INC. | $32.19 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $29.65 | 2021 | |
| Pfizer INC. | $25.50 | 2023 | |
| Corcept Therapeutics | $15.84 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.19 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $13.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.04 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.84 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Clapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.